# HS-10502

Source: https://onco.cc/drugs/hs-10502/  
OnCo record `hs-10502` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

HS-10502 is an experimental pill being studied to block a DNA-repair enzyme in cancer cells.

## Summary

The registry describes HS-10502 as a PARP1-specific selective inhibitor. The linked registry records distinguish recruiting, closed, and discontinued studies; those states do not establish comparative efficacy or approval.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-10-06
- Modality: Small-molecule PARP1 inhibitor
- Mechanism: The registry describes HS-10502 as a PARP1-specific selective inhibitor.

## Sources

- ClinicalTrials.gov NCT05740956: https://clinicaltrials.gov/study/NCT05740956
- ClinicalTrials.gov NCT06769425: https://clinicaltrials.gov/study/NCT06769425

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Prostate cancer](https://onco.cc/cancers/prostate/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- targets: [PARP](https://onco.cc/targets/parp/)
- trials: [A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct05740956/), [HS-10502 Combination Treatment in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct06769425/)

---
JSON: https://onco.cc/api/v1/entities/hs-10502.json